Grauer Andreas 4

What Happened

• Andreas Grauer, Chief Medical Officer of Sagimet Biosciences (SGMT), was granted a derivative equity award on May 28, 2026 covering 35,000 shares. The filing reports an acquisition price of $0.00 and a reported total value of $0 (this is a grant/option award, not an open-market purchase).

Key Details

• Transaction date: 2026-05-28; Filing date: 2026-06-01 (filed after the typical 2-business-day Form 4 window).
• Instrument: Derivative award (option) covering 35,000 shares; reported price $0.00; reported value $0.
• Vesting: The shares underlying the option vest and become exercisable in 48 equal monthly installments beginning May 28, 2026 (footnote F1), subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A (award/grant).

Context

• This was a compensation grant (an option award) that vests over time — not an exercised option or immediate stock purchase/sale. No cash was reported as paid and no shares were sold or exercised at grant. Such time‑based option grants are common for employee retention and do not by themselves indicate insider buying or selling sentiment.